MTOR and pancreatic neuroendocrine tumor: Everolimus, an oral inhibitor of the mammalian target of rapamycin (mTOR), and sunitinib, a multi-targeted tyrosine kinase inhibitor, have both shown promising results in pancreatic NETs (11, 12).